Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP)
São Paulo, Brazil
NCT Number: NCT04446702
The aim of the study is to describe the long-term use of abobotulinumtoxinA (Dysport®) in adult subjects affected with upper limb spasticity (ULS) +/- lower limb spasticity (LLS) who received treatment with Dysport® for a minimum of three injections cycles at the Instituto de Medicina Física e Reabilitação do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (IMREA HC FMUSP) in Brazil.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
São Paulo, Brazil
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: Baseline (first Dysport® injection)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Outcome will be assessed according following reasons: due to medical need, unplanned need and not recorded
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019).
Outcome will be assessed according following reasons: side effects (e.g. excessive weakness, hematoma), contractures, absence of clinical response, long lasting clinical improvement, patient lost follow up and other.
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
The MAS is a six-point scale to grade muscle tone in the injected muscle from 0 (no increase in tone) to 4 (affected parts rigid in flexion or extension). Upper limb: shoulder abduction, elbow flexion, elbow extension, wrist flexion, wrist extension and fingers flexion. Lower limb: hip flexion, hip adduction, hip abduction, knee flexion, knee extension, ankle dorsiflexion and ankle plantar flexion.
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Subscales and total scores of FIM will be measured. The FIM is a method for categorising patients on a seven-point scale (range 1 to 7). It comprises of 18 items, grouped into 2 subscales (motor and cognition). The motor subscale includes: eating, grooming, bathing, dressing upper body, dressing lower body, toileting, bladder management, bowel management, transfers - bed/chair/wheelchair, transfers - toilet, transfers - bath/shower, walk/wheelchair and stairs. The cognition subscale includes: comprehension, expression, social interaction, problem solving and memory. The Scores are summed to obtain a total score that can range between 18 and 126.
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
The pain Visual Analogue Scale (VAS) is a numeric graphic rating scale (NGRS) of self-reported symptoms. Scores are recorded as whole numbers between zero and 10, where zero indicates no pain symptom at all, and 10 indicates a as bad as it could be.
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Gait Pattern Modification in patients with LLS is based on physician´s clinical evaluation and it will be evaluated for each lower limb (left and right) or both according to pre-specified patterns: equinismus, foot inversion, knee hyperextension, adduction, mowing abduction, thigh elevation, hip elevation, false trendelenburg, not able to walk. The Gait Pattern Improvement is described based on patient´s perception of gait. The patients respond Yes or No and if Yes the % of improvement is replied
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
List the systemic drug therapies, including: antispasticity medications (e.g. Baclofen, Tizanidin, Dantrolene), simple pain medications (e.g. paracetamol or NSAIDS), neuropathic pain and spasticity medications (e.g. Gabapentin, Pregabalin, Amitriptyline), opioids, phenol, alcool or other neurolytic agents.
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
List the non-drug concomitant therapies, including occupational therapy, physiotherapy and others (e.g.: orthotics, serial casting, splinting, electric stimulation)
Time frame: From baseline (visit 1) and up to the last injection during data record (January 1st, 2006 to July 31st, 2019)
Adverse events will be assessed according to incidence, intensity/grade (mild, moderate and severe), causality (related and not related to the product), outcome (the overall association between an exposure to a drug and an outcome) and action taken. All Adverse Events (AEs) (including fatal events and Serious Adverse Events (SAEs)) and special situation (pregnancy, overdose, off-label use) will be reported with the number and proportion of events. The incidence will be provided and classified by System Organ Class and Preferred Term
Ipsen
Industry
Retrospective Real-life Study From One Brazilian Reference Centre Assessing Long-term Experience in the Treatment of Adult Spasticity With AbobotulinumtoxinA (RETURN Study)
Acronym: RETURN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07712471
Muscle Hypertonia, Muscle Spasticity
A Coruña, Spain
View Trial DetailsNCT07273591
Brain Diseases, Cardiovascular Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT07346430
Anxiety, Anxiety Disorders
Cairo, Egypt
View Trial DetailsNCT07301606
Brain Diseases, Cardiovascular Diseases
Faisalabad, Punjab Province, Pakistan
View Trial Details